![](/images/graphics-bg.png)
SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy
المؤلفون المشاركون
Okuno, Scott H.
Dickson, Mark A.
Pollock, Raphael E.
George, Suzanne
Chugh, Rashmi
Choy, Edwin
Ballman, Karla
Chen, James
Patel, Rajiv M.
Hoering, Antje
Patel, Shreyaskumar
المصدر
العدد
المجلد 2018، العدد 2018 (31 ديسمبر/كانون الأول 2018)، ص ص. 1-9، 9ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2018-10-24
دولة النشر
مصر
عدد الصفحات
9
التخصصات الرئيسية
الملخص EN
Histone deacetylase inhibitors (HDACi) can reverse chemoresistance, enhance chemotherapy-induced cytotoxicity, and reduce sarcoma proliferation in cell lines and animal models.
We sought to determine the safety and toxicity of mocetinostat and its ability to reverse chemoresistance when administered with gemcitabine in patients with metastatic leiomyosarcoma resistant to prior gemcitabine-containing therapy.
Participants with metastatic leiomyosarcoma received mocetinostat orally, 70 mg per day, three days per week, increasing to 90 mg after three weeks if well tolerated.
Gemcitabine was administered at 1,000 mg/m2 intravenously at 10 mg/m2/minute on days five and 12 of every 21-day cycle.
Disease response was evaluated with CT or MRI.
Twenty participants with leiomyosarcoma were evaluated for toxicity.
Median time to disease progression was 2.0 months (95% CI 1.54–3.12).
Eighteen participants were evaluated for radiologic response by RECIST 1.1.
Best responses included one PR and 12 SD.
Tumor size reduced in 3 patients.
Most common toxicities were fatigue, thrombocytopenia, anemia, nausea, and anorexia.
One patient experienced a significant pericardial adverse event.
No study-related deaths were observed.
Rechallenging with gemcitabine by adding mocetinostat was feasible and demonstrated modest activity in patients with leiomyosarcoma.
Further studies are needed to better define the role of HDAC inhibitors in patients with metastatic leiomyosarcoma.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Choy, Edwin& Ballman, Karla& Chen, James& Dickson, Mark A.& Chugh, Rashmi& George, Suzanne…[et al.]. 2018. SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy. Complexity،Vol. 2018, no. 2018, pp.1-9.
https://search.emarefa.net/detail/BIM-1212803
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Choy, Edwin…[et al.]. SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy. Complexity No. 2018 (2018), pp.1-9.
https://search.emarefa.net/detail/BIM-1212803
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Choy, Edwin& Ballman, Karla& Chen, James& Dickson, Mark A.& Chugh, Rashmi& George, Suzanne…[et al.]. SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy. Complexity. 2018. Vol. 2018, no. 2018, pp.1-9.
https://search.emarefa.net/detail/BIM-1212803
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1212803
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)